Expanded Clinical Use of Nasalferon in COVID-19

Intranasal use of recombinant human interferon alfa-2b in the treatment of asymptomatic and mild symptomatic low-risk patients with suspected and confirmed COVID-19. (COVID-19) - NASALFERON-SNS

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

RPCEC

Registry ID

RPCEC00000396

Enrollment

200

Registered

2021-11-10

Start date

2021-11-15

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 COVID-19 SARS-CoV-2

Interventions

Nasalferon: Recombinant human interferon alpha 2b solution for nasal administration (Nasalferon) with strength of 5 million international units per milliliter. Dosage: one drop in each nostril twice a

Interferon alpha-2

Interferon alpha

Interferons

Administration, Intranasal

Nasalferon, drops

Eligibility

Sex/Gender

All

Age

10 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Low risk suspect, mild symptomatic, with positive antigen test. 2. Confirmed low risk, asymptomatic and mild symptomatic, with positive PCR. 3. Voluntariness of the patient or legal representative.

Exclusion criteria

Exclusion criteria: 1. Individuals confirmed COVID-19 and classified as medium and high risk. 2. Individuals with hypersensitivity to thiomersal (thimerosal). 3. Individuals with hypersensitivity to interferon alpha

Design outcomes

Primary

Measure	Time frame
Occurrence of adverse events associated with treatment (Yes or No, Description of adverse events). Measurement time: daily during the patient's treatment time (10 days).	—

Secondary

Measure	Time frame
1. Intensity of the adverse event (CLasified as mild, moderate or severe). Measurement time: daily during the patient's treatment times (10 days). 2. Causation of the adverse event (Classified as definitive, probable, possible and doubtful). Measurement time: daily during the patient's treatment times (10 days). 3. Severity of the adverse event (classified as serious and non-serious). Measurement time: daily during the patient's treatment times (10 days).	—

Measure

Time frame

1. Intensity of the adverse event (CLasified as mild, moderate or severe). Measurement time: daily during the patient's treatment times (10 days). 2. Causation of the adverse event (Classified as definitive, probable, possible and doubtful). Measurement time: daily during the patient's treatment times (10 days). 3. Severity of the adverse event (classified as serious and non-serious). Measurement time: daily during the patient's treatment times (10 days).

—

Countries

Cuba

Contacts

Public ContactHugo Nodarse Cuni

Center for Genetic Engineering and Biotechnology (CIGB).

hugo.nodarse@cigb.edu.cu

Outcome results

None listed

Source: RPCEC (via WHO ICTRP) · Data processed: Apr 4, 2026